Trial evaluating the efficacy and the safety of FOLFIRINOX3 treatment in patients with unresectable locally advanced or metastatic pancreatic cancer in first line of chemotherapy
Phase 1
Recruiting
- Conditions
- Patients with unresectable locally advanced or metastatic pancreatic cancer in first line of chemotherapyMedDRA version: 21.0Level: LLTClassification code: 10033606Term: Pancreatic cancer non-resectable Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10033605Term: Pancreatic cancer metastatic Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-505889-29-01
- Lead Sponsor
- Centr Georges Francois Leclerc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method